ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Tuesday, November 9, 2010 at 9:00 a.m. EST to review the Company’s third quarter financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.
To access the conference call, please dial (877) 407-9210 (domestic) or (201) 689-8049 (international). A replay of the call will be available from 11:00 a.m. Eastern Standard Time on November 9th until December 10, 2010 at midnight. To access the replay, please dial (877) 660-6853 (domestic) or (201) 612-7415 (international) and reference the account # 286 and the conference id # 359917. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at http://www.inhibitex.com.
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1 clinical development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines.
For additional information about the Company, please visit www.inhibitex.com.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
KEYWORDS: United States North America Georgia
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Hospitals Infectious Diseases Pharmaceutical Research Science